{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:58:34Z","timestamp":1789779514029,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Center","award":["NCC1310120"],"award-info":[{"award-number":["NCC1310120"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.bbrc.2013.10.095","type":"journal-article","created":{"date-parts":[[2013,10,27]],"date-time":"2013-10-27T04:01:04Z","timestamp":1382846464000},"page":"655-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition"],"prefix":"10.1016","volume":"441","author":[{"given":"Ju-Hwa","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ae-Ran","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Kee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungpil","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2013.10.095_b0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2013.10.095_b0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2013.10.095_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2008.06.035","article-title":"A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I\u2013IV uterine carcinosarcoma","volume":"111","author":"Makker","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/COC.0b013e3181af30d3","article-title":"Prediction of chemotherapy response with platinum and taxane in the advanced stage of ovarian and uterine carcinosarcoma: a clinical implication of in vitro drug resistance assay","volume":"33","author":"Matsuo","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0025","first-page":"96","article-title":"Taxanes, microtubules and chemoresistant breast cancer","volume":"1785","author":"McGrogan","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2013.10.095_b0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2008.05.017","article-title":"Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution","volume":"110","author":"Pectasides","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/COC.0b013e3181931049","article-title":"Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes","volume":"33","author":"Rivera","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0040","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkl563","article-title":"Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo","volume":"59","author":"Vivas","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbrc.2013.10.095_b0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.actatropica.2003.10.012","article-title":"Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria","volume":"89","author":"Pukrittayakamee","year":"2004","journal-title":"Acta Trop."},{"key":"10.1016\/j.bbrc.2013.10.095_b0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/48.2.179","article-title":"Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum","volume":"48","author":"Pradines","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbrc.2013.10.095_b0055","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","article-title":"Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells","volume":"10","author":"Berdelle","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2013.10.095_b0060","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1016\/j.bmcl.2009.10.081","article-title":"Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine","volume":"19","author":"Fernandes","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2013.10.095_b0065","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1074\/jbc.M110.210047","article-title":"Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production","volume":"286","author":"Hamacher-Brady","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2013.10.095_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/0008-5472.CAN-12-2464","article-title":"Chloroquine in cancer therapy: a double-edged sword of autophagy","volume":"73","author":"Kimura","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2013.10.095_b0075","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cncr.22562","article-title":"Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia","volume":"109","author":"Madden","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2013.10.095_b0080","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bcp.2004.05.003","article-title":"Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model","volume":"68","author":"Martirosyan","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0085","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0006-2952(96)00556-4","article-title":"Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine","volume":"52","author":"Riffkin","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0090","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2013.10.095_b0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/187152010793498645","article-title":"Doxycycline in mitochondrial mediated pathway of apoptosis: a systematic review","volume":"10","author":"Sagar","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bbrc.2013.10.095_b0100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1101\/gad.2016111","article-title":"Pancreatic cancers require autophagy for tumor growth","volume":"25","author":"Yang","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2013.10.095_b0105","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.bmcl.2009.07.044","article-title":"Atovaquone derivatives as potent cytotoxic and apoptosis inducing agents","volume":"19","author":"Zhou","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2013.10.095_b0110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cells1030558","article-title":"Autophagy and transporter-based multi-drug resistance","volume":"1","author":"Kumar","year":"2012","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2013.10.095_b0115","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.4161\/auto.24921","article-title":"Dual inhibition of autophagy and the AKT pathway in prostate cancer","volume":"9","author":"Lamoureux","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.bbrc.2013.10.095_b0120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/gt.2012.96","article-title":"Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination","volume":"20","author":"Tang","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbrc.2013.10.095_b0125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/ijo.2010.879","article-title":"HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization","volume":"38","author":"Kim","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0130","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.bcp.2009.03.007","article-title":"7-Diethylamino-3(2\u2032-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells","volume":"77","author":"Kim","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0135","doi-asserted-by":"crossref","first-page":"13169","DOI":"10.3390\/ijms131013169","article-title":"Lower salinomycin concentration increases apoptotic detachment in high-density cancer cells","volume":"13","author":"Kim","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2013.10.095_b0140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2011.12.141","article-title":"Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest","volume":"418","author":"Kim","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2013.10.095_b0145","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10637-011-9685-6","article-title":"Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest","volume":"30","author":"Kim","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bbrc.2013.10.095_b0150","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1476-5381.2010.01089.x","article-title":"Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein","volume":"162","author":"Kim","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bcp.2009.09.008","article-title":"Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines","volume":"79","author":"Kim","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.10.095_b0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/1087057110385230","article-title":"Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds","volume":"16","author":"Szeremy","year":"2011","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bbrc.2013.10.095_b0165","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1126\/science.1205216","article-title":"Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets","volume":"333","author":"Yuan","year":"2011","journal-title":"Science"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X13017762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X13017762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T18:16:48Z","timestamp":1646936208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X13017762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0006291X13017762"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2013.10.095","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2013.10.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}